Onychopathy Induced by Nivolumab: A Targeted Immunotherapy

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor on T-cells and blocks its interaction with PD-L1 and PD-L2, releasing the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahoor, Fatima, Ahmed, Najia, Afzal, Ghazal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381033/
https://www.ncbi.nlm.nih.gov/pubmed/35989738
http://dx.doi.org/10.7759/cureus.26950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381033/
https://www.ncbi.nlm.nih.gov/pubmed/35989738
http://dx.doi.org/10.7759/cureus.26950

Ejemplares similares